Press Releases

Date Title
10/17/17
Summary ToggleNeothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Women’s Health Company Printer Friendly Version SAN DIEGO, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) and Evofem Biosciences, Inc. today announced they have entered into a definitive agreement under which privately-held Evofem Biosciences will merge with a wholly-owned subsidiary of Neothetics in an all-stock transaction.
08/10/17
Summary ToggleNeothetics Provides Business Update and Reports Second Quarter 2017 Financial Results Printer Friendly Version SAN DIEGO , Aug. 10, 2017 (GLOBE NEWSWIRE) -- Neothetics , Inc. (NASDAQ:NEOT) provided a business update and reported financial results for the second quarter 2017. In July 2017 , Neothetics announced that its Board of Directors unanimously approved plans to initiate a process to explore and review
07/10/17
Summary ToggleNeothetics Announces Review of Strategic Alternatives Printer Friendly Version SAN DIEGO , July 10, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) announced today that its Board of Directors has unanimously approved plans to initiate a process to explore and review a range of strategic alternatives focusing on seeking an acquisition, business combination or
06/26/17
Summary ToggleNeothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat Printer Friendly Version LIPO-202 did not show efficacy in the reduction of submental fat SAN DIEGO , June 26, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced top-line safety and efficacy results
05/11/17
Summary ToggleNeothetics Provides Business Update and Reports First Quarter 2017 Financial Results Printer Friendly Version SAN DIEGO , May 11, 2017 (GLOBE NEWSWIRE) -- Neothetics , Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a business update and reported financial results for the first quarter 2017.
05/04/17
Summary ToggleNeothetics to Provide a Business Update and Release First Quarter 2017 Financial Results Thursday, May 11th, 2017 Printer Friendly Version SAN DIEGO , May 04, 2017 (GLOBE NEWSWIRE) -- Neothetics , Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, announced today that it will provide a business update and release its first quarter 2017 financial results before the
04/05/17
Summary ToggleNeothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical Asset Printer Friendly Version SAN DIEGO , April 05, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced the issuance of U.S. Patent Number 9,597,531 by the United States Patent and Trademark Office (USPTO). 
03/29/17
Summary ToggleNeothetics to Present at the 16th Annual Needham Healthcare Conference Printer Friendly Version SAN DIEGO , March 29, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that Susan A. Knudson , Neothetics’ Chief Financial Officer, will present at the 16 th Annual Needham Healthcare Conference on Wednesday, April 5 th at 12:50 PM ,  Eastern Time at the Westin Grand Central
03/23/17
Summary ToggleNeothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results Printer Friendly Version SAN DIEGO , March 23, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016. “We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to
03/20/17
Summary ToggleNeothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat Printer Friendly Version SAN DIEGO , March 20, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the